{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:22:09Z","timestamp":1788175329074,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012551","name":"Sichuan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2024NSFSC2108"],"award-info":[{"award-number":["2024NSFSC2108"]}],"id":[{"id":"10.13039\/100012551","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejpb.2026.115213","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:42:05Z","timestamp":1786117325000},"page":"115213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["18\u03b2-glycyrrhetinic acid as a promising co-former for co-amorphous systems fabrication"],"prefix":"10.1016","volume":"227","author":[{"given":"Jia","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangwen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5917-7674","authenticated-orcid":false,"given":"Xiaoju","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9046-2702","authenticated-orcid":false,"given":"Jialu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-0156","authenticated-orcid":false,"given":"Qian","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1706-396X","authenticated-orcid":false,"given":"Ningbo","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8330-0660","authenticated-orcid":false,"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8234-0292","authenticated-orcid":false,"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6936-9197","authenticated-orcid":false,"given":"Hailu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2026.115213_b0005","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.apsb.2021.05.014","article-title":"Pharmaceutical amorphous solid dispersion: a review of manufacturing strategies","volume":"11","author":"Bhujbal","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejpb.2026.115213_b0010","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/j.2042-7158.2010.01030.x","article-title":"Pharmaceutical applications of cyclodextrins: basic science and product development","volume":"62","author":"Loftsson","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115213_b0015","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.addr.2007.05.010","article-title":"Salt formation to improve drug solubility","volume":"59","author":"Serajuddin","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2026.115213_b0020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/molecules21010042","article-title":"The prodrug approach: a successful tool for improving drug solubility","volume":"21","author":"Jornada","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2026.115213_b0025","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40164-025-00656-1","article-title":"Developments in nanotechnology approaches for the treatment of solid tumors","volume":"14","author":"Venturini","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ejpb.2026.115213_b0030","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3390\/ijms27020915","article-title":"Enhancing the water solubility and efficacy of anticancer drugs using hydroxypropyl-\u03b2-cyclodextrin","volume":"27","author":"Kubota","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2026.115213_b0035","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.apsb.2021.03.030","article-title":"Pharmaceutical cocrystals: a review of preparations, physicochemical properties and applications","volume":"11","author":"Guo","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejpb.2026.115213_b0040","doi-asserted-by":"crossref","first-page":"18759","DOI":"10.3390\/molecules201018759","article-title":"Polymorph impact on the bioavailability and stability of poorly soluble drugs","volume":"20","author":"Censi","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2026.115213_b0045","article-title":"Advances in the development of amorphous solid dispersions: the role of polymeric carriers","volume":"18","author":"Zhang","year":"2023","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115213_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122098","article-title":"Physical stability and dissolution behaviors of amorphous pharmaceutical solids: role of surface and interface effects","volume":"625","author":"Shi","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115213_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2026.107493","article-title":"Glycyl-l-histidyl-l-lysine as a novel co-former in co-amorphous systems: enhanced aqueous solubility and physical stability","volume":"220","author":"Huang","year":"2026","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115213_b0060","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ejpb.2013.03.014","article-title":"Amino acids as co-amorphous stabilizers for poorly water soluble drugs\u2013Part 1: preparation, stability and dissolution enhancement","volume":"85","author":"L\u00f6bmann","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115213_b0065","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1021\/acs.molpharmaceut.5b00295","article-title":"Formation mechanism of coamorphous drug-amino acid mixtures","volume":"12","author":"Jensen","year":"2015","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115213_b0070","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejpb.2016.06.020","article-title":"Influence of variation in molar ratio on co-amorphous drug-amino acid systems","volume":"107","author":"Jensen","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115213_b0075","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1039\/D5PM00146C","article-title":"Exploring hot melt extrusion in the formation of exemestane\/amino acid co-amorphous systems","volume":"2","author":"Partheniadis","year":"2025","journal-title":"RSC Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115213_b0080","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejps.2016.08.022","article-title":"Development of a screening method for co-amorphous formulations of drugs and amino acids","volume":"95","author":"Kasten","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115213_b0085","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1021\/acs.molpharmaceut.7b00932","article-title":"Drug-excipient interactions: effect on molecular mobility and physical stability of ketoconazole-organic acid coamorphous systems","volume":"15","author":"Fung","year":"2018","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115213_b0090","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejpb.2018.07.016","article-title":"Organic acids as co-formers for co-amorphous systems \u2013 influence of variation in molar ratio on the physicochemical properties of the co-amorphous systems","volume":"131","author":"Wu","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115213_b0095","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1021\/acs.cgd.5c00606","article-title":"Coamorphous solid forms of posaconazole with carboxylic acid: preparation, characterization, and pharmacokinetic study","volume":"25","author":"Dhodi","year":"2025","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejpb.2026.115213_b0100","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1021\/acs.molpharmaceut.5c00858","article-title":"Coamorphous system of vitamin B2 and chlorogenic acid: enhanced physicochemical property and synergistic anti-inflammatory potential","volume":"22","author":"Chen","year":"2025","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115213_b0105","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ijpharm.2013.04.032","article-title":"Coamorphous repaglinide-saccharin with enhanced dissolution","volume":"450","author":"Gao","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115213_b0110","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1021\/acs.cgd.5b00349","article-title":"Coamorphous lurasidone hydrochloride\u2013saccharin with charge-assisted hydrogen bonding interaction shows improved physical stability and enhanced dissolution with ph-independent solubility behavior","volume":"15","author":"Qian","year":"2015","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejpb.2026.115213_b0115","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ijpharm.2018.07.063","article-title":"Aspartame as a co-former in co-amorphous systems","volume":"549","author":"Wu","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115213_b0120","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1021\/acs.molpharmaceut.8b01229","article-title":"Transformations between co-amorphous and co-crystal systems and their influence on the formation and physical stability of co-amorphous systems","volume":"16","author":"Wu","year":"2019","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115213_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124592","article-title":"Study on co-amorphous emerging solubilization behavior after gelation during dissolution: the importance of complexation and anti-crystallization","volume":"664","author":"Pu","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115213_b0130","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/03602532.2015.1029634","article-title":"Potential drug interactions associated with glycyrrhizin and glycyrrhetinic acid","volume":"47","author":"Feng","year":"2015","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.ejpb.2026.115213_b0135","first-page":"79","volume":"26","author":"Andersen","year":"2007","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.ejpb.2026.115213_b0140","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.yrtph.2006.06.002","article-title":"Risk and safety assessment on the consumption of Licorice root (Glycyrrhiza sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin","volume":"46","author":"Isbrucker","year":"2006","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115213_b0145","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s13738-015-0744-3","article-title":"Ultrasound-assisted dispersive liquid\u2013liquid microextraction method combined with HPLC-fluorescence detection for the determination of glycyrrhetinic acid in liquorice and liquorice-derived food products","volume":"13","author":"You","year":"2015","journal-title":"J. Iran. Chem. Soc."},{"key":"10.1016\/j.ejpb.2026.115213_b0150","doi-asserted-by":"crossref","DOI":"10.1007\/s10973-026-15568-3","article-title":"Predicting glass transition temperatures of unstable drugs using co-amorphous mixtures","author":"Green","year":"2026","journal-title":"J. Therm. Anal. Calorim."},{"key":"10.1016\/j.ejpb.2026.115213_b0155","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1021\/mp500539g","article-title":"Investigating albendazole desmotropes by solid-state NMR spectroscopy","volume":"12","author":"Chattah","year":"2015","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115213_b0160","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1002\/jps.22072","article-title":"Enantiotropically related albendazole polymorphs","volume":"99","author":"Pranzo","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115213_b0165","doi-asserted-by":"crossref","first-page":"5169","DOI":"10.1021\/acs.cgd.0c00382","article-title":"Polymorphism and particle formation pathway of carbamazepine during sonoprecipitation from ionic liquid solutions","volume":"20","author":"Prasad","year":"2020","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejpb.2026.115213_b0170","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1021\/mp400299a","article-title":"Indomethacin: new polymorphs of an old drug","volume":"10","author":"Surwase","year":"2013","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115213_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120649","article-title":"Considerations for the selection of co-formers in the preparation of co-amorphous formulations","volume":"602","author":"Yarlagadda","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115213_b0180","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1208\/s12249-017-0734-0","article-title":"Coamorphous loratadine-citric acid system with enhanced physical stability and bioavailability","volume":"18","author":"Wang","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2026.115213_b0185","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3390\/molecules26020452","article-title":"Grafting of 18\u03b2-glycyrrhetinic acid and sialic acid onto chitosan to produce a new amphipathic chitosan derivative: synthesis, characterization, and cytotoxicity","volume":"26","author":"Quan","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2026.115213_b0190","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1021\/acs.cgd.4c01208","article-title":"Multicomponent crystal forms of albendazole for bioavailability improvement","volume":"25","author":"Adegbolagun","year":"2025","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejpb.2026.115213_b0195","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jddst.2017.11.003","article-title":"Albendazole nanocrystals: optimization, spectroscopic, thermal and anthelmintic studies","volume":"43","author":"Koradia","year":"2018","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2026.115213_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.106086","article-title":"Role of polymers in the physical and chemical stability of amorphous solid dispersion: a case study of carbamazepine","volume":"169","author":"Yu","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115213_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.143694","article-title":"Intermolecular interactions in melt-quenched co-amorphous acetaminophen-ascorbic Acid-PVP K30: FTIR, XRD, and DFT analysis","volume":"1349","author":"Ibrahim","year":"2026","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejpb.2026.115213_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125876","article-title":"Inhalable delivery of salmeterol xinafoate-ciclesonide co-amorphous for asthma treatment: prediction, preparation and evaluation","volume":"681","author":"Bian","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115213_b0215","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1021\/mp2002973","article-title":"Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen","volume":"8","author":"L\u00f6bmann","year":"2011","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115213_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120894","article-title":"Co-amorphous systems of sinomenine with nonsteroidal anti-inflammatory drugs: a strategy for solubility improvement, sustained release, and drug combination therapy against rheumatoid arthritis","volume":"606","author":"Chen","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115213_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121235","article-title":"Crystallization kinetics and molecular dynamics of binary coamorphous systems of nimesulide and profen analogs","volume":"610","author":"Zhang","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115213_b0230","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1080\/17425247.2020.1796631","article-title":"Co-amorphous systems for the delivery of poorly water-soluble drugs: recent advances and an update","volume":"17","author":"Han","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2026.115213_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2025.114972","article-title":"Sulfasalazine\u2013quercetin co-amorphous systems: sustained release behaviors and enhanced pharmacokinetics","volume":"220","author":"Deng","year":"2026","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126002341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126002341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:12:54Z","timestamp":1788174774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126002341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":47,"alternative-id":["S0939641126002341"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115213","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"18\u03b2-glycyrrhetinic acid as a promising co-former for co-amorphous systems fabrication","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115213","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115213"}}